AU732392B2 - Ret ligand (retL) for stimulating neural and renal growth - Google Patents

Ret ligand (retL) for stimulating neural and renal growth Download PDF

Info

Publication number
AU732392B2
AU732392B2 AU34729/97A AU3472997A AU732392B2 AU 732392 B2 AU732392 B2 AU 732392B2 AU 34729/97 A AU34729/97 A AU 34729/97A AU 3472997 A AU3472997 A AU 3472997A AU 732392 B2 AU732392 B2 AU 732392B2
Authority
AU
Australia
Prior art keywords
seq
leu
ser
ret
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU34729/97A
Other languages
English (en)
Other versions
AU3472997A (en
Inventor
Richard L. Cate
Catherine Hession
Michele Sanicola-Nadel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of AU3472997A publication Critical patent/AU3472997A/en
Application granted granted Critical
Publication of AU732392B2 publication Critical patent/AU732392B2/en
Assigned to BIOGEN IDEC MA INC. reassignment BIOGEN IDEC MA INC. Request to Amend Deed and Register Assignors: BIOGEN, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU34729/97A 1996-05-08 1997-05-07 Ret ligand (retL) for stimulating neural and renal growth Ceased AU732392B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US1742796P 1996-05-08 1996-05-08
US60/017427 1996-05-08
US1930096P 1996-06-07 1996-06-07
US60/019300 1996-06-07
US2185996P 1996-07-16 1996-07-16
US60/021859 1996-07-16
US4353397P 1997-04-11 1997-04-11
US60/043533 1997-04-11
PCT/US1997/007726 WO1997044356A2 (en) 1996-05-08 1997-05-07 RET LIGAND (RetL) FOR STIMULATING NEURAL AND RENAL GROWTH

Publications (2)

Publication Number Publication Date
AU3472997A AU3472997A (en) 1997-12-09
AU732392B2 true AU732392B2 (en) 2001-04-26

Family

ID=27360789

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34729/97A Ceased AU732392B2 (en) 1996-05-08 1997-05-07 Ret ligand (retL) for stimulating neural and renal growth

Country Status (24)

Country Link
EP (2) EP0914339B1 (https=)
JP (1) JP2002515743A (https=)
KR (2) KR20060024843A (https=)
CN (2) CN1163509C (https=)
AT (1) ATE335003T1 (https=)
AU (1) AU732392B2 (https=)
BG (2) BG64907B1 (https=)
BR (1) BR9710665A (https=)
CA (1) CA2253871C (https=)
CZ (1) CZ296516B6 (https=)
DE (1) DE69736428T2 (https=)
DK (1) DK0914339T3 (https=)
EA (1) EA002544B1 (https=)
EE (1) EE9800377A (https=)
ES (1) ES2270465T3 (https=)
IL (1) IL126918A (https=)
IS (1) IS2361B (https=)
NO (2) NO323612B1 (https=)
NZ (1) NZ332706A (https=)
PT (1) PT914339E (https=)
RO (1) RO120343B1 (https=)
SK (1) SK286115B6 (https=)
TR (2) TR200103297T2 (https=)
WO (1) WO1997044356A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696259B1 (en) 1995-11-13 2004-02-24 Licentia Ltd. Assays using glial cell line-derived neurotrophic factor receptors
EP0846764A3 (en) * 1996-11-27 1998-09-30 Smithkline Beecham Plc Glial cell line-derived neurotrophic factor alpha receptor family
EP0948620A2 (en) * 1996-12-06 1999-10-13 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6025157A (en) 1997-02-18 2000-02-15 Genentech, Inc. Neurturin receptor
WO1998036072A1 (en) * 1997-02-18 1998-08-20 Genentech, Inc. Neurturin receptor
US6372453B1 (en) 1997-02-18 2002-04-16 Genetech, Inc. Neurturin receptor
US6777196B2 (en) 1997-02-18 2004-08-17 Genentech, Inc. Neurturin receptor
CA2291705A1 (en) * 1997-04-17 1998-10-22 Washington University Receptors for tgf-.beta.-related neurotrophic factors
WO1998053069A2 (en) * 1997-05-20 1998-11-26 Human Genome Sciences, Inc. Gdnf receptors
EP1007072A4 (en) * 1997-05-22 2002-06-26 Cephalon Inc RECEPTORS NEUROTROPHER FACTORS FROM A GLIA CELL LINE
CA2291608C (en) * 1997-05-30 2004-04-13 Amgen Inc. Neurotrophic factor receptors
WO1999049039A2 (en) 1998-03-23 1999-09-30 Genentech, Inc. GFRα3 AND ITS USES
US7026138B1 (en) 1998-03-23 2006-04-11 Genentech, Inc. Polynucleotides encoding GFRα3
US20020055467A1 (en) 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
WO2001016169A2 (en) * 1999-09-01 2001-03-08 Biogen, Inc. RET LIGAND 5 (Retl5) FROM HUMAN AND MOUSE
NZ581460A (en) 2003-01-31 2010-02-26 Biogen Idec Inc Polymer conjugates of mutated neublastin
NZ604708A (en) 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
US10023855B2 (en) * 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
US20150177246A1 (en) * 2012-07-26 2015-06-25 Lsip, Llc Fusion gene of cep55 gene and ret gene
CA2910553A1 (en) 2013-04-30 2014-11-06 Universite De Montreal Novel biomarkers for acute myeloid leukemia
BR112018000808A2 (pt) 2015-07-16 2018-09-04 Array Biopharma Inc compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
JP2024522938A (ja) * 2021-06-03 2024-06-21 フンダサン デー.アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド 脳-脂肪回路を介してilc2および肥満度を制御する神経-間葉単位

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5185154A (en) 1989-02-02 1993-02-09 Liposome Technology, Inc. Method for instant preparation of a drug containing large unilamellar vesicles
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
JP3021800B2 (ja) 1990-07-24 2000-03-15 セイコーエプソン株式会社 半導体装置及びその製造方法
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
FR2693107B1 (fr) 1992-07-01 1994-09-23 Chauvin Laboratoire Moyens pour la prévention de la cataracte secondaire.
AU1404395A (en) * 1993-12-13 1995-07-03 Biogen, Inc. Anti-mullerian hormone receptor polypeptides and antibodies thereto
AU718979B2 (en) * 1995-11-13 2000-05-04 Urmas Arumae Glial cell line-derived neurotrophic factor receptors
ATE247667T1 (de) * 1996-03-14 2003-09-15 Genentech Inc Gdnf-rezeptor und dessen verwendung
US6455277B1 (en) * 1996-04-22 2002-09-24 Amgen Inc. Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides

Also Published As

Publication number Publication date
CN1232469A (zh) 1999-10-20
DE69736428D1 (de) 2006-09-14
EP0914339B1 (en) 2006-08-02
CA2253871A1 (en) 1997-11-27
RO120343B1 (ro) 2005-12-30
SK286115B6 (sk) 2008-03-05
IS2361B (is) 2008-05-15
NO985231D0 (no) 1998-11-09
BR9710665A (pt) 1999-08-17
JP2002515743A (ja) 2002-05-28
DE69736428T2 (de) 2007-08-30
PT914339E (pt) 2006-12-29
TR200103297T2 (tr) 2002-06-21
NO323612B1 (no) 2007-06-18
IL126918A (en) 2007-06-03
IL126918A0 (en) 1999-09-22
CZ296516B6 (cs) 2006-04-12
ATE335003T1 (de) 2006-08-15
CN1163509C (zh) 2004-08-25
TR199802252T2 (xx) 1999-02-22
DK0914339T3 (da) 2006-12-04
NO985231L (no) 1999-01-08
AU3472997A (en) 1997-12-09
WO1997044356A3 (en) 1998-02-19
EA002544B1 (ru) 2002-06-27
NO324957B1 (no) 2008-01-14
CN1624126A (zh) 2005-06-08
EP1757617A1 (en) 2007-02-28
CZ361598A3 (cs) 1999-03-17
WO1997044356A2 (en) 1997-11-27
IS4884A (is) 1998-11-06
ES2270465T3 (es) 2007-04-01
NO20065528L (no) 1999-01-08
NZ332706A (en) 1999-10-28
KR20050056275A (ko) 2005-06-14
BG109433A (en) 2007-08-31
KR100587556B1 (ko) 2006-06-08
SK152498A3 (en) 1999-08-06
EA199800990A1 (ru) 1999-06-24
EE9800377A (et) 1999-04-15
BG102973A (en) 1999-08-31
BG64907B1 (bg) 2006-08-31
CA2253871C (en) 2005-04-26
KR20060024843A (ko) 2006-03-17
EP0914339A2 (en) 1999-05-12

Similar Documents

Publication Publication Date Title
AU732392B2 (en) Ret ligand (retL) for stimulating neural and renal growth
US6677135B1 (en) Ret ligand (RetL) for stimulating neutral and renal growth
EP0907735B1 (en) Modulators of tissue regeneration
WO2001016169A2 (en) RET LIGAND 5 (Retl5) FROM HUMAN AND MOUSE
HK1021821A1 (en) Ret ligand 3 (retl3) for stimulating neural and renal growth
HK1021821B (en) Ret ligand 3 (retl3) for stimulating neural and renal growth
HK1101184A (en) Ret ligand (retl) for stimulating neural and renal growth
KR100554901B1 (ko) 신경및신장증식을자극하기위한RET리간드(RetL)
MXPA98009309A (en) Compounds that promote tej growth
CA2496906A1 (en) Ret ligand (retl) for stimulating neural and renal growth

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)